Seeliger Daniel, Schulz Patrick, Litzenburger Tobias, Spitz Julia, Hoerer Stefan, Blech Michaela, Enenkel Barbara, Studts Joey M, Garidel Patrick, Karow Anne R
a Division Research Germany; Boehringer Ingelheim Pharma GmbH & Co. KG ; Biberach/Riss , Germany.
MAbs. 2015;7(3):505-15. doi: 10.1080/19420862.2015.1017695.
The application of monoclonal antibodies as commercial therapeutics poses substantial demands on stability and properties of an antibody. Therapeutic molecules that exhibit favorable properties increase the success rate in development. However, it is not yet fully understood how the protein sequences of an antibody translates into favorable in vitro molecule properties. In this work, computational design strategies based on heuristic sequence analysis were used to systematically modify an antibody that exhibited a tendency to precipitation in vitro. The resulting series of closely related antibodies showed improved stability as assessed by biophysical methods and long-term stability experiments. As a notable observation, expression levels also improved in comparison with the wild-type candidate. The methods employed to optimize the protein sequences, as well as the biophysical data used to determine the effect on stability under conditions commonly used in the formulation of therapeutic proteins, are described. Together, the experimental and computational data led to consistent conclusions regarding the effect of the introduced mutations. Our approach exemplifies how computational methods can be used to guide antibody optimization for increased stability.
单克隆抗体作为商业治疗药物的应用对抗体的稳定性和性质提出了很高的要求。具有良好性质的治疗分子可提高开发成功率。然而,目前尚未完全了解抗体的蛋白质序列如何转化为良好的体外分子性质。在这项工作中,基于启发式序列分析的计算设计策略被用于系统地修饰一种在体外有沉淀倾向的抗体。通过生物物理方法和长期稳定性实验评估,所得一系列密切相关的抗体显示出更高的稳定性。值得注意的是,与野生型候选抗体相比,表达水平也有所提高。本文描述了用于优化蛋白质序列的方法,以及用于确定在治疗性蛋白质制剂常用条件下对稳定性影响的生物物理数据。实验和计算数据共同得出了关于引入突变影响的一致结论。我们的方法例证了如何使用计算方法来指导抗体优化以提高稳定性。